TABLE 3.
Results of the longitudinal mixed effects regression models examining the relationship of baseline biomarker levels to CSF biomarker trajectories
| Outcome: Aβ42/Aβ40 | Outcome: Aβ42/Aβ40 | Outcome: p‐tau181 | Outcome: t‐tau | |||||
|---|---|---|---|---|---|---|---|---|
| Model predictor | Estimate (95% CI) | p‐value | Estimate (95% CI) | p‐value | Estimate (95% CI) | p‐value | Estimate (95% CI) | p‐value |
| Time | 0.017 (–0.003, 0.038) | 0.098 | 0.017 (–0.003, 0.038) | 0.101 | 0.034 (0.014, 0.054) | 0.001 | 0.045 (0.023, 0.067) | < 0.001 |
| Time x time | –0.001 (–0.002, 0.000) | 0.078 | –0.001 (–0.002, 0.000) | 0.087 | 0.002 (0.001, 0.003) | < 0.001 | 0.001 (0.000,0.002) | 0.049 |
| APOE ε4 | –0.490 (–0.692, –0.288) | < 0.001 | –0.449 (–0.636, –0.261) | < 0.001 | –0.086 (–0.298, 0.126) | 0.427 | –0.073 (–0.298, 0.152) | 0.525 |
| APOE ε4 x time | –0.045 (–0.059, –0.030) | < 0.001 | –0.043 (–0.058, –0.029) | < 0.001 | 0.030 (0.011, 0.050) | 0.002 | 0.029 (0.012, 0.046) | 0.001 |
| Baseline t‐tau | –0.295 (–0.397, –0.193) | < 0.001 | — | — | — | — | — | — |
| Baseline t‐tau x time | –0.009 (–0.018, 0.001) | 0.066 | — | — | — | — | — | — |
| Baseline p‐tau181 | — | — | –0.438 (–0.534, –0.343) | < 0.001 | — | — | — | — |
| Baseline p‐tau181 x time | — | — | –0.006 (–0.016, 0.003) | 0.208 | — | — | — | — |
| Baseline Aβ42/Aβ40 | — | — | — | — | –0.455 (–0.562, –0.348) | < 0.001 | –0.320 (–0.434, –0.206) | < 0.001 |
| Baseline Aβ42/Aβ40 x time | — | — | — | — | –0.031 (–0.043, –0.020) | < 0.001 | –0.022 (–0.033, –0.011) | < 0.001 |
Note: Different models were estimated for each CSF measure. Models were also adjusted for all variables indicated in Table 2.
Abbreviations: Aβ, amyloid beta; APOE, apolipoprotein E; CI, confidence interval; CSF, cerebrospinal fluid; p‐tau, phosphorylated tau; t‐tau, total tau.